Standard BioTools reports Q1 EPS (7c), consensus (4c)

Reports Q1 revenue $40.8M, consensus $40.1M. “Standard BioTools (LAB) delivered a solid first quarter in line with our expectations, reflecting focused execution in a challenging Life Sciences macro backdrop,” said Michael Egholm, President and Chief Executive Officer of Standard BioTools. “We remain grounded and disciplined, driving a 29% year-over-year improvement in adjusted EBITDA through Standard BioTools Business System (SBS). We believe our unique model, world class operational platform and healthy capital position will allow us to continue to take advantage of the current environment and deliver shareholder value over time.”